Continental Advisors’s Gilead Sciences GILD Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.95M | Sell |
28,367
-4,500
| -14% | -$630K | 2.02% | 18 |
|
|
2025
Q4 | $4.03M | Sell |
32,867
-1,500
| -4% | -$182K | 1.7% | 18 |
|
|
2025
Q3 | $3.81M | Sell |
34,367
-1,500
| -4% | -$170K | 1.65% | 20 |
|
|
2025
Q2 | $3.98M | Sell |
35,867
-9,000
| -20% | -$958K | 1.86% | 19 |
|
|
2025
Q1 | $5.03M | Sell |
44,867
-11,500
| -20% | -$1.19M | 2.81% | 15 |
|
|
2024
Q4 | $5.21M | Sell |
56,367
-4,000
| -7% | -$360K | 2.4% | 15 |
|
|
2024
Q3 | $5.06M | Sell |
60,367
-15,000
| -20% | -$1.14M | 2.44% | 15 |
|
|
2024
Q2 | $5.17M | Buy |
75,367
+11,464
| +18% | +$765K | 2.27% | 15 |
|
|
2024
Q1 | $4.68M | Sell |
63,903
-11,000
| -15% | -$846K | 1.89% | 18 |
|
|
2023
Q4 | $6.07M | Sell |
74,903
-7,000
| -9% | -$545K | 2.37% | 9 |
|
|
2023
Q3 | $6.14M | Hold |
81,903
| – | – | 3.27% | 7 |
|
|
2023
Q2 | $6.31M | Sell |
81,903
-16,500
| -17% | -$1.32M | 2.85% | 8 |
|
|
2023
Q1 | $8.16M | Buy |
98,403
+25,000
| +34% | +$2.07M | 4.36% | 3 |
|
|
2022
Q4 | $6.3M | Sell |
73,403
-10,534
| -13% | -$834K | 3.3% | 8 |
|
|
2022
Q3 | $5.18M | Sell |
83,937
-4,000
| -5% | -$252K | 3.05% | 10 |
|
|
2022
Q2 | $5.43M | Hold |
87,937
| – | – | 3.28% | 8 |
|
|
2022
Q1 | $5.23M | Buy |
87,937
+3,000
| +4% | +$192K | 2.58% | 11 |
|
|
2021
Q4 | $6.17M | Sell |
84,937
-15,000
| -15% | -$1.03M | 2.6% | 7 |
|
|
2021
Q3 | $6.98M | Sell |
99,937
-24,000
| -19% | -$1.69M | 2.96% | 8 |
|
|
2021
Q2 | $8.53M | Sell |
123,937
-3,000
| -2% | -$200K | 3.93% | 6 |
|
|
2021
Q1 | $8.2M | Buy |
126,937
+37,500
| +42% | +$2.42M | 3.8% | 3 |
|
|
2020
Q4 | $5.21M | Buy |
89,437
+29,000
| +48% | +$1.75M | 2.38% | 11 |
|
|
2020
Q3 | $3.82M | Buy |
60,437
+18,000
| +42% | +$1.25M | 2.02% | 9 |
|
|
2020
Q2 | $3.27M | Buy |
42,437
+5,000
| +13% | +$383K | 1.75% | 15 |
|
|
2020
Q1 | $2.8M | Buy |
37,437
+10,000
| +36% | +$691K | 2.08% | 12 |
|
|
2019
Q4 | $1.78M | Sell |
27,437
-3,391
| -11% | -$221K | 0.86% | 44 |
|
|
2019
Q3 | $1.95M | Hold |
30,828
| – | – | 1.15% | 34 |
|
|
2019
Q2 | $2.08M | Hold |
30,828
| – | – | 1.18% | 39 |
|
|
2019
Q1 | $2M | Sell |
30,828
-26,872
| -47% | -$1.79M | 0.93% | 44 |
|
|
2018
Q4 | $3.61M | Hold |
57,700
| – | – | 1.1% | 34 |
|
|
2018
Q3 | $4.46M | Sell |
57,700
-9,700
| -14% | -$733K | 0.97% | 37 |
|
|
2018
Q2 | $4.78M | Buy |
67,400
+14,900
| +28% | +$1.05M | 1.19% | 33 |
|
|
2018
Q1 | $3.96M | Hold |
52,500
| – | – | 1% | 40 |
|
|
2017
Q4 | $3.76M | Hold |
52,500
| – | – | 0.81% | 43 |
|
|
2017
Q3 | $4.25M | Sell |
52,500
-18,200
| -26% | -$1.39M | 0.97% | 38 |
|
|
2017
Q2 | $5M | Sell |
70,700
-6,500
| -8% | -$433K | 1.13% | 26 |
|
|
2017
Q1 | $5.24M | Buy |
77,200
+33,500
| +77% | +$2.36M | 1.17% | 21 |
|
|
2016
Q4 | $3.13M | Buy |
43,700
+6,700
| +18% | +$498K | 0.85% | 34 |
|
|
2016
Q3 | $2.93M | Buy |
+37,000
| New | +$3.01M | 0.82% | 43 |
|
Other funds holding GILD
VCM
VPM
Continental Advisors's GILD Position: Q1 2026 in Review
Continental Advisors reduced its Gilead Sciences (GILD) stake by 14% in Q1 2026, selling an estimated $630K and leaving 28,367 shares worth $3.95M. The position accounts for 2.02% of the portfolio, ranked #18.
Continental Advisors first reported a position in GILD in Q3 2016 and has held it in 39 quarters since. The position peaked at $8.53M in Q2 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.
- Continental Advisors held 28,367 shares of Gilead Sciences worth $3.95M as of Q1 2026.
- Continental Advisors sold 4,500 Gilead Sciences shares in Q1 2026, an estimated $630K.
- Gilead Sciences made up 2.02% of Continental Advisors's portfolio in Q1 2026, its #18 holding.
- Continental Advisors first reported a position in Gilead Sciences in Q3 2016 and has held it in 39 quarters since.
- Continental Advisors's Gilead Sciences position peaked at $8.53M in Q2 2021.
- 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.
Based on Continental Advisors's 13F filing for Q1 2026, filed 15 May 2026.